PhaseRx (PhaseRx) Buyback Yield % : 0.00 (As of May. 31, 2024)

View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

PhaseRx's current buyback yield was 0.00%.

PhaseRx Buyback Yield % Historical Data

The historical data trend for PhaseRx's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Buyback Yield % Chart

PhaseRx Annual Data

Trend

Dec14

Dec15

Dec16

Buyback Yield %

-90.92

PhaseRx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Buyback Yield %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of PhaseRx's Buyback Yield %

For the Biotechnology subindustry, PhaseRx's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseRx's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where PhaseRx's Buyback Yield % falls into.

PhaseRx Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

PhaseRx's Buyback Yield for the fiscal year that ended in Dec. 2016 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	16.475)	/	18.119965
	=	-90.92%

PhaseRx's annualized Buyback Yield for the quarter that ended in Sep. 2017 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	9.586046
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2017) data.

PhaseRx Buyback Yield % Related Terms

Thank you for viewing the detailed overview of PhaseRx's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseRx (PhaseRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119

Website

http://www.phaserx.com

PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.

Executives

Gordon Brandt	officer: Chief Medical Officer	410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr	director	300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio • 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm • 05-24-2016